Massive-scale genomic risk assessment to inform precision medicine for diabetes
Official title: Massive-scale genomic risk assessment to inform precision medicine across the spectrum of monogenic and common forms of diabetes
Funded at Broad Institute, INC. · NIH-11596832 · Data updated 2026-11-12
A large study aims to map how genetic differences influence different forms of diabetes to guide personalized care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 19, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $64,682 |
| NIH project number | 3R01DK140545-02S1 |
| Project ID | NIH-11596832 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with or at risk for type 1, type 2, or monogenic diabetes, including those of diverse ancestry.
✕Less likely to help
People without diabetes or with non-genetic forms of diabetes may see limited direct benefit.
What this research studies
This project looks at how dozens or hundreds of genetic variants affect risk and classification of diabetes across populations, including monogenic and common forms. Researchers will integrate genomic data with clinical information to create clearer guidelines for diagnosing and reporting genetic results. The effort focuses on improving how doctors interpret rare and common variants, especially in people with non-European ancestry, so patients receive more precise, actionable information. Overall, the goal is to move toward personalized medicine that matches treatments to each person’s genetic profile.
Why it matters
Potential benefit: If successful, patients could receive more accurate diagnoses and tailored treatments based on their genetic risk.
How similar studies have gone: Previous genomic studies have linked variants to diabetes risk, but this project seeks a unified, cross-ancestry framework.
Where this research is happening
-
Broad Institute, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Mercader, Josep Maria — Broad Institute, INC.
- Study coordinator: Mercader, Josep Maria
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.